Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Genetic analysis of the CYP21A2 gene in neonatal dried blood spots from children with transiently elevated 17-hydroxyprogesterone

J. Malikova, F. Votava, Z. Vrzalova, J. Lebl, O. Cinek,

. 2012 ; 77 (2) : 187-194.

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc13000953

Grantová podpora
NS9981 MZ0 CEP - Centrální evidence projektů

BACKGROUND: Neonatal screening for congenital adrenal hyperplasia (CAH) identifies a certain proportion of newborns with transient moderate elevation of 17-hydroxyprogesterone (17-OHP). These children require regular follow-up until normalization of their 17-OHP levels. We investigated the possibility of reducing the individuals' recall rates by using genetic methods on their original neonatal dried blood spots. PATIENTS AND METHODS: We analysed neonatal dried blood spots from 753 subjects with transiently elevated levels of 17-OHP. The CYP21A2 gene was sequenced to detect point mutations, and the presence of CYP21A2 was further confirmed by two methods utilizing the difference between CYP21A2 and its CYP21A1P pseudogene in the sequence of exon 3 (8-bp deletion). The accuracy of the methods was verified using samples from 70 subjects with known CYP21A2 mutations and 181 healthy children. RESULT: Among the 701 successfully sequenced samples from subjects with transiently elevated 17-OHP, 670 (95%) had no point mutations or novel variants in the CYP21A2 gene. We found no individuals carrying genotypes consistent with the diagnosis of CAH (i.e. homozygotes or compound heterozygotes for point mutations, large deletions or rearrangements). However, 21 heterozygous carriers of known point mutations that cause the classic and nonclassic forms of CAH were identified. Additionally, we detected eight heterozygous and two homozygous point variants with unknown functional significance. CONCLUSION: Although CAH caused by 21-hydroxylase deficiency could be genetically excluded with a reasonable degree of confidence in 95% of the genotyped subjects that had transiently elevated 17-OHP, the performance of the tests was suboptimal when performed using dried blood spots and time-consuming in comparison with the current practice of repeated measurements of 17-OHP. The introduction of this method into clinical practice seems to be impractical at this stage.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc13000953
003      
CZ-PrNML
005      
20141111122756.0
007      
ta
008      
130108s2012 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/j.1365-2265.2012.04358.x $2 doi
035    __
$a (PubMed)22313422
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Malikova, Jana $u Department of Pediatrics, 2nd Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
245    10
$a Genetic analysis of the CYP21A2 gene in neonatal dried blood spots from children with transiently elevated 17-hydroxyprogesterone / $c J. Malikova, F. Votava, Z. Vrzalova, J. Lebl, O. Cinek,
520    9_
$a BACKGROUND: Neonatal screening for congenital adrenal hyperplasia (CAH) identifies a certain proportion of newborns with transient moderate elevation of 17-hydroxyprogesterone (17-OHP). These children require regular follow-up until normalization of their 17-OHP levels. We investigated the possibility of reducing the individuals' recall rates by using genetic methods on their original neonatal dried blood spots. PATIENTS AND METHODS: We analysed neonatal dried blood spots from 753 subjects with transiently elevated levels of 17-OHP. The CYP21A2 gene was sequenced to detect point mutations, and the presence of CYP21A2 was further confirmed by two methods utilizing the difference between CYP21A2 and its CYP21A1P pseudogene in the sequence of exon 3 (8-bp deletion). The accuracy of the methods was verified using samples from 70 subjects with known CYP21A2 mutations and 181 healthy children. RESULT: Among the 701 successfully sequenced samples from subjects with transiently elevated 17-OHP, 670 (95%) had no point mutations or novel variants in the CYP21A2 gene. We found no individuals carrying genotypes consistent with the diagnosis of CAH (i.e. homozygotes or compound heterozygotes for point mutations, large deletions or rearrangements). However, 21 heterozygous carriers of known point mutations that cause the classic and nonclassic forms of CAH were identified. Additionally, we detected eight heterozygous and two homozygous point variants with unknown functional significance. CONCLUSION: Although CAH caused by 21-hydroxylase deficiency could be genetically excluded with a reasonable degree of confidence in 95% of the genotyped subjects that had transiently elevated 17-OHP, the performance of the tests was suboptimal when performed using dried blood spots and time-consuming in comparison with the current practice of repeated measurements of 17-OHP. The introduction of this method into clinical practice seems to be impractical at this stage.
650    _2
$a 17-alfa-hydroxyprogesteron $x krev $7 D019326
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a genetické testování $x metody $7 D005820
650    _2
$a lidé $7 D006801
650    _2
$a novorozenec $7 D007231
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a novorozenecký screening $7 D015997
650    _2
$a bodová mutace $x genetika $7 D017354
650    _2
$a pseudogeny $x genetika $7 D011544
650    _2
$a steroid-21-hydroxylasa $x genetika $7 D013255
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Votava, Felix
700    1_
$a Vrzalova, Zuzana
700    1_
$a Lebl, Jan
700    1_
$a Cinek, Ondrej
773    0_
$w MED00009474 $t Clinical endocrinology $x 1365-2265 $g Roč. 77, č. 2 (2012), s. 187-194
856    41
$u https://pubmed.ncbi.nlm.nih.gov/22313422 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20130108 $b ABA008
991    __
$a 20141111122809 $b ABA008
999    __
$a ok $b bmc $g 963735 $s 799117
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2012 $b 77 $c 2 $d 187-194 $i 1365-2265 $m Clinical endocrinology $n Clin Endocrinol (Oxf) $x MED00009474
GRA    __
$a NS9981 $p MZ0
LZP    __
$a Pubmed-20130108

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...